TS-HDS autoantibody: clinical characterization and utility from real-world tertiary care center experience.

MLA

Chompoopong, Pitcha, et al. “TS-HDS Autoantibody: Clinical Characterization and Utility from Real-World Tertiary Care Center Experience.” Journal of Neurology, vol. 270, no. 9, Sept. 2023, pp. 4523–28. EBSCOhost, https://doi.org/10.1007/s00415-023-11798-9.

APA

Chompoopong, P., Rezk, M., Mirman, I., Berini, S. E., Dyck, P. J. B., Mauermann, M., Shouman, K., Klein, C., Mills, J. R., & Dubey, D. (2023). TS-HDS autoantibody: clinical characterization and utility from real-world tertiary care center experience. Journal of Neurology, 270(9), 4523–4528. https://doi.org/10.1007/s00415-023-11798-9

Chicago

Chompoopong, Pitcha, Mohamed Rezk, Igal Mirman, Sarah E. Berini, P. James B. Dyck, Michelle Mauermann, Kamal Shouman, Christopher Klein, John R. Mills, and Divyanshu Dubey. 2023. “TS-HDS Autoantibody: Clinical Characterization and Utility from Real-World Tertiary Care Center Experience.” Journal of Neurology 270 (9): 4523–28. doi:10.1007/s00415-023-11798-9.